Pragmatic Management of EGFR-Mutant NSCLC After Progression on Osimertinib: Canadian Expert Perspectives.

doi:10.3390/curroncol33080465

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Pragmatic Management of EGFR-Mutant NSCLC After Progression on Osimertinib: Canadian Expert Perspectives.

Current oncology (Toronto, Ont.) - 5 Aug 2026

Daaboul Nathalie, Agulnik Jason S, Bahig Houda, Blais Normand, Boucher Marie-Ève, Bouchard Nicole, Denault Marie-Hélène, Desmeules Patrice, Fiset Pierre Olivier, Florescu Marie, Jao Kevin, Labbé Catherine, Lecavalier-Barsoum Magali, Pepe Carmela, Shieh Benjamin, Stock-Martineau Sophie, Marcoux Nicolas

Abstract excerpt

The management of epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after progression on osimertinib is becoming increasingly complex, particularly in Canada, where access to diagnostic testing and newer therapies remains uneven. Although treatment is evolving with regimens such as amivantamab-lazertinib (MARIPOSA/MARIPOSA-2) and osimertinib plus chemotherapy (FLAURA2), access to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Acrylamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aniline Compounds

Share to Antineoplastic Agents

Share to Canada

Share to ErbB Receptors

Share to Indoles

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 42645370
DOI: 10.3390/curroncol33080465
PMCID: PMC13510353

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.